Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
With significant revisions to the EU WEEE Directive anticipated for 2026, including higher collection targets and potentially new reporting obligations, how should a medical device manufacturer, as a ...
With significant updates to EU environmental regulations, including revisions to the WEEE Directive and various national Extended Producer Responsibility (EPR) frameworks anticipated around 2026, how ...
With international standards like ISO 10993 undergoing periodic revisions, how can medical device manufacturers develop a robust strategy for selecting a contract research organization (CRO) for bioco...
As internationally recognized biocompatibility standards continue to evolve, what is a comprehensive and proactive framework for medical device manufacturers to adapt their biological evaluation strat...
As the transitional arrangements for medical device compliance in Great Britain approach their deadlines, how should a non-UK manufacturer develop a comprehensive strategy for selecting a UK Responsib...
With significant updates to the UK's medical device regulations on the horizon, non-UK manufacturers face a critical deadline to ensure compliance. A key requirement is the appointment of a UK Respons...
For a non-US medical device manufacturer preparing to enter the US market, the requirement to designate a US Agent can seem like a simple administrative step. However, the choice of a US Agent has sig...
With significant updates to the EU's regulatory landscape for cosmetics expected through 2026, how can a non-EU brand move beyond a basic checklist to select a truly effective Responsible Person (RP) ...
For manufacturers of connected medical devices, such as an integrated continuous glucose monitoring system (iCGM) governed by regulations like 21 CFR 862.1355, preparing for global market entry requir...
For a medical device premarket submission, what are the key components of a robust cybersecurity documentation package that effectively demonstrates a proactive security posture to regulators like the...
With international standards for biocompatibility, such as the ISO 10993 series, undergoing periodic revisions, how can medical device manufacturers proactively adapt their regulatory strategies for s...
With international biocompatibility standards continually evolving, how can medical device manufacturers move beyond a simple checklist approach and develop a robust, risk-based biological evaluation ...
When budgeting for a UK Responsible Person (UKRP) for 2026 and beyond, what are the key factors and service models that influence the overall cost? While specific fees vary between providers, understa...
For medical device manufacturers based outside the United Kingdom, appointing a UK Responsible Person (UKRP) is a critical step for market access. However, understanding the associated costs, particul...
When selecting an EU Authorised Representative (AR) under the Medical Device Regulation (EU) 2017/745 (MDR), what specific operational and strategic criteria should a non-EU manufacturer prioritize to...
When a non-EU cosmetic brand plans to enter the European market, designating an EU-based Responsible Person (RP) is a fundamental legal requirement. While the concept seems straightforward, the scope ...
For a non-EU-based manufacturer of a connected medical device, such as a Software as a Medical Device (SaMD) or a wearable biosensor that processes personal health data, navigating European market ent...
What role do Special Controls play in the premarket review for certain Class II in vitro diagnostic (IVD) devices? For many Class II medical devices, General Controls alone are insufficient to provid...
Given the significantly enhanced responsibilities and joint liability assigned to Authorized Representatives (AR) under the EU Medical Device Regulation (MDR), and in light of recent MDCG guidance cla...
When selecting an EU Authorized Representative (AR) under Regulation (EU) 2017/745 (MDR), what comprehensive due diligence process should a non-EU manufacturer implement beyond verifying the AR's phys...